Decas Harvests Cranberry IP

CARVER, Mass.Decas Botanical Synergies, LLC has signed an exclusive license agreement with JLB Inc., which develops and owns intellectual property involving cranberry (Vaccinium macrocarpon) and other related species. The deal, which includes a purchase option, covers patents secured in the United States (#5,474,774; #5,525,341; #5,646,178; and #5,650,432), United Kingdom (#0752871) and Australia (#703158 and #708657) for cranberry extract and various anti-adhesion activities and benefits to non-viral infection control. Also, the agreement includes a non-exclusive license, with a sublicensing option, of a U.S. Patent covering a plant proanthocyanidin extracts inhibition of bacteria (w/P-type fimbrae) adhesion.

Signing an exclusive license and purchase option for these patents is an important milestone for DBS, said Doug Klaiber, CEO of Decas Botanical Synergies. Given the broad coverage of these significant and fundamental patents, we now have the ability to protect our research investment, increase market share and defend our global leadership position in the rapidly growing cranberry nutraceutical market. It is our intention to leverage the intellectual property via the introduction of new innovative products and through strategic partnerships and supply agreements.